111 related articles for article (PubMed ID: 24443523)
1. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
Valentino JD; Li J; Zaytseva YY; Mustain WC; Elliott VA; Kim JT; Harris JW; Campbell K; Weiss H; Wang C; Song J; Anthony L; Townsend CM; Evers BM
Clin Cancer Res; 2014 Mar; 20(5):1212-22. PubMed ID: 24443523
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Babichev Y; Kabaroff L; Datti A; Uehling D; Isaac M; Al-Awar R; Prakesch M; Sun RX; Boutros PC; Venier R; Dickson BC; Gladdy RA
J Transl Med; 2016 Mar; 14():67. PubMed ID: 26952093
[TBL] [Abstract][Full Text] [Related]
3. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL
Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530
[TBL] [Abstract][Full Text] [Related]
4. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor.
Di Florio A; Sancho V; Moreno P; Delle Fave G; Jensen RT
Biochim Biophys Acta; 2013 Mar; 1833(3):573-82. PubMed ID: 23220008
[TBL] [Abstract][Full Text] [Related]
6. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.
Yadav SS; Li J; Stockert JA; O'Connor J; Herzog B; Elaiho C; Galsky MD; Tewari AK; Yadav KK
Oncotarget; 2016 Nov; 7(46):76181-76196. PubMed ID: 27783994
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3K/AKT signaling using BKM120 reduced the proliferation and migration potentials of colorectal cancer cells and enhanced cisplatin-induced cytotoxicity.
Khameneh SC; Sari S; Razi S; Yousefi AM; Bashash D
Mol Biol Rep; 2024 Mar; 51(1):420. PubMed ID: 38483663
[TBL] [Abstract][Full Text] [Related]
8. PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Sai J; Owens P; Novitskiy SV; Hawkins OE; Vilgelm AE; Yang J; Sobolik T; Lavender N; Johnson AC; McClain C; Ayers GD; Kelley MC; Sanders M; Mayer IA; Moses HL; Boothby M; Richmond A
Clin Cancer Res; 2017 Jul; 23(13):3371-3384. PubMed ID: 28003307
[No Abstract] [Full Text] [Related]
9. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.
Semenova G; Stepanova DS; Dubyk C; Handorf E; Deyev SM; Lazar AJ; Chernoff J
Oncogene; 2017 Sep; 36(38):5421-5431. PubMed ID: 28534510
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.
Lee CL; Cremona M; Farrelly A; Workman JA; Kennedy S; Aslam R; Carr A; Madden S; O'Neill B; Hennessy BT; Toomey S
Cancer Biol Ther; 2023 Dec; 24(1):2223388. PubMed ID: 37326340
[TBL] [Abstract][Full Text] [Related]
11. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways.
Zwang NA; Zhang R; Germana S; Fan MY; Hastings WD; Cao A; Turka LA
Am J Transplant; 2016 Sep; 16(9):2624-38. PubMed ID: 27017850
[TBL] [Abstract][Full Text] [Related]
12. A MEK inhibitor arrests the cell cycle of human conjunctival fibroblasts and improves the outcome of glaucoma filtration surgery.
Lee J; Honjo M; Aihara M
Sci Rep; 2024 Jan; 14(1):1871. PubMed ID: 38253821
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of acute myeloid leukemia by dual PI3K/mTOR inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model.
Taghiloo S; Ajami A; Alizadeh-Navaei R; Asgarian-Omran H
Int Immunopharmacol; 2023 Dec; 125(Pt B):111211. PubMed ID: 37956488
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms.
Cella CA; Cazzoli R; Fazio N; De Petro G; Gaudenzi G; Carra S; Romanenghi M; Spada F; Grossi I; Pallavicini I; Minucci S; Vitale G
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37855330
[TBL] [Abstract][Full Text] [Related]
15. Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors.
Whitt J; Hong WS; Telange RR; Lin CP; Bibb J; Beebe DJ; Chen H; Jaskula-Sztul R
Cancer Gene Ther; 2020 Dec; 27(12):898-909. PubMed ID: 32029905
[TBL] [Abstract][Full Text] [Related]
16. Elevated sortilin expression discriminates functional from non-functional neuroendocrine tumors and enables therapeutic targeting.
Bolduan F; Wetzel A; Giesecke Y; Eichhorn I; Alenina N; Bader M; Willnow TE; Wiedenmann B; Sigal M
Front Endocrinol (Lausanne); 2024; 15():1331231. PubMed ID: 38694940
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition.
Passacantilli I; Capurso G; Archibugi L; Calabretta S; Caldarola S; Loreni F; Delle Fave G; Sette C
Oncotarget; 2014 Jul; 5(14):5381-91. PubMed ID: 25026292
[TBL] [Abstract][Full Text] [Related]
18. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
Roper J; Sinnamon MJ; Coffee EM; Belmont P; Keung L; Georgeon-Richard L; Wang WV; Faber AC; Yun J; Yilmaz ÖH; Bronson RT; Martin ES; Tsichlis PN; Hung KE
Cancer Lett; 2014 Jun; 347(2):204-11. PubMed ID: 24576621
[TBL] [Abstract][Full Text] [Related]
19. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
Liu WL; Gao M; Tzen KY; Tsai CL; Hsu FM; Cheng AL; Cheng JC
Oncotarget; 2014 Jun; 5(11):3662-72. PubMed ID: 25004403
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
Vandamme T; Peeters M; Dogan F; Pauwels P; Van Assche E; Beyens M; Mortier G; Vandeweyer G; de Herder W; Van Camp G; Hofland LJ; Op de Beeck K
J Mol Endocrinol; 2015 Apr; 54(2):137-47. PubMed ID: 25612765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
